The Effects of Neprilysin on Glucagon-like Peptide-1

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 May 2022 Results of a pooled analysis (in 2 randomized crossover trials with sacubitril/valsartan vs control study and sacubitril/valsartan and sitagliptin vs sitagliptin study) to determine whether angiotensin receptor-neprilysin inhibitor treatment acutely affects circulating concentrations of bioactive CNP and its molecular amino-terminal precursor published in the Clinical Chemistry
11 Jun 2019 Results hypothesizing that Sacubitril/Valsartan attenuates neprilysin-dependent degradation of GLP-1, and has synergistic effects when combined with Sitagliptin using two open labeled trials presented at the 79th Annual Scientific Sessions of the American Diabetes Association
14 May 2019 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com